BME:PHMBiotechs
The Bull Case For PharmaMar (BME:PHM) Could Change Following FDA Priority Review For Lurbinectedin
PharmaMar and Jazz Pharmaceuticals previously announced that the US Food and Drug Administration granted Priority Review to their lurbinectedin submission for relapsed small-cell lung cancer, alongside a US licensing deal that could be worth up to US$1.00 billion.
This combination of accelerated regulatory attention and a high-value commercial partnership highlights how lurbinectedin has become a central asset in PharmaMar’s oncology pipeline.
Now we’ll examine how FDA Priority Review for...